Posted On: 12/12/2016 2:34:55 PM
Post# of 72447
Dr. Sonis' comments on B-OM:
“The ability of PMX-30063 to mitigate ulcerative mucositis in pre-clinical studies is significant and exciting,” commented Stephen T. Sonis, DMD, DMSc, Chief Medical Officer at Biomodels where the studies were performed, and a Professor of Oral Medicine at Harvard’s School of Dental Medicine and world-renowned expert in the clinical treatment and research of cancer related mucosal toxicities. “Radiation and chemotherapy are life-saving treatments for cancer patients, but the development of extensive painful lesions in the mouth, tongue and throat renders many patients unable to eat, speak or tolerate therapy. The results seen with PMX-30063 are extremely promising and support further testing as a new therapeutic agent to address this substantial unmet medical need.”
http://www.businesswire.com/news/home/2011051...-Promising
“The ability of PMX-30063 to mitigate ulcerative mucositis in pre-clinical studies is significant and exciting,” commented Stephen T. Sonis, DMD, DMSc, Chief Medical Officer at Biomodels where the studies were performed, and a Professor of Oral Medicine at Harvard’s School of Dental Medicine and world-renowned expert in the clinical treatment and research of cancer related mucosal toxicities. “Radiation and chemotherapy are life-saving treatments for cancer patients, but the development of extensive painful lesions in the mouth, tongue and throat renders many patients unable to eat, speak or tolerate therapy. The results seen with PMX-30063 are extremely promising and support further testing as a new therapeutic agent to address this substantial unmet medical need.”
http://www.businesswire.com/news/home/2011051...-Promising
(1)
(0)
